A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02406742 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: CC-122
DRUG: Ibrutinib
DRUG: Obinutuzumab

Sponsor

Celgene